Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 9/20 | 0.38 |
| ▸ | CCNK | O75909 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4222280 | 0.88 | CNR1 (0.36) | HPGDEP300CCNKCCNA2CDK2 | |
| SCHEMBL4227771 | 0.83 | CCNK (0.40) | OPRM1CCNKCCNA2CDK2CDK12 | |
| SCHEMBL4228168 | 0.75 | CCR6 (0.40) | — | |
| SCHEMBL4232751 | 0.70 | — | — | |
| Trifluoroacetic Acid SCHEMBL4237396 | 0.69 | EP300 (0.52) | EP300 | |
| SCHEMBL4233785 | 0.66 | MTNR1A (0.52) | HPGD | |
| SCHEMBL3539266 | 0.64 | CNR1 (0.53) | ABCB1HPGDABCG2 | |
| SCHEMBL11782431 | 0.63 | MLYCD (0.56) | MLYCD | |
| SCHEMBL3833319 | 0.62 | MLYCD (0.62) | MLYCD | |
| SCHEMBL6602168 | 0.62 | MEN1 (0.53) | MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2096104-A1 | Organic diamines as mGluR7 modulators | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080242698-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242698-A1 | Organic Compounds | AOC1, OTC, ODC1 | ABCB1 264/4885HPGD 1276/4885ABCG2 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.